Digital Pathology Market by Offering (Hardware, Software, Service), Application (Diagnostic, Drug Discovery, Training), End User (Hospital, Academic Institute)

Description

List of Tables

Digital Pathology Market Size, Share, Forecast, & Trends Analysis by Offering (Hardware [Scanner, Tissue Microarray], Software [Information Management, Image Analysis], Service), Application (Diagnostic, Drug Discovery), End User-Global Forecast to 2030

The digital pathology market is projected to reach $1.86 billion by 2030 at a CAGR of 8.7% from 2023 to 2030.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges.

The growth of this market is driven by the rising prevalence of chronic diseases, the increasing adoption of digital pathology solutions to enhance lab efficiency, and the widening applications of digital pathology in companion diagnostics and drug development. However, the lack of reimbursements for digital pathology services restrains the growth of this market.

Furthermore, the rising demand for personalized medicine, the launch of affordable scanners for private pathology practices, and developing economies are generating significant opportunities for digital pathology solutions providers. However, the legal and regulatory hurdles in digital pathology and the shortage of trained pathologists are major challenges in this market.

The report offers a competitive landscape based on an extensive assessment of the product portfolios, geographic presence, and key strategic developments of leading market players during the last four years (2020-2023). The key players operating in the digital pathology market are 3DHISTECH Ltd. (Hungary), Leica Microsystems (a subsidiary of Danaher Corporation) (Germany), Hamamatsu Photonics K.K. (Japan), Nikon Corporation (Japan), Visiopharm A/S (Denmark), Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Glencoe Software, Inc. (U.S.), XIFIN, Inc. (U.S.), and PerkinElmer Inc. (U.S.).

Based on offering, in 2023, the hardware segment is expected to account for the largest share of the digital pathology market. The large market share of this segment is attributed to the increased demand for precise & accurate diagnosis and an increase in patients requiring in vitro tests.

Based on application, in 2023, the disease diagnosis segment is expected to account for the largest share of the digital pathology market. The large market share of this segment is attributed to the high burden of chronic diseases, the high adoption of teleconsulting, and rising awareness about the importance of early disease diagnosis.

Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of the digital pathology market. The large market share of this segment is attributed to the increased availability and affordability of advanced technological pathology solutions at hospitals, the higher preference for hospitals/clinics as a primary center for care, and the high volume of patient inflow in hospitals & clinics.

An in-depth analysis of the geographical scenario in the digital pathology market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the digital pathology market. Furthermore, in 2023, the U.S. is expected to hold the major market share in North America. Market growth in the U.S. is driven by the digitization of pathology services, high investments in R&D, the high adoption of advanced technologies, and the increased demand for reliable and faster diagnostics.

Scope of the Report:

Digital Pathology Market Assessment-by Offering

Hardware
- Slide Scanners
Bright Field
Other Scanners
- Tissue Microarray
- Other Hardware
Software
- Image Analysis Software
- Information Management System
- Other Software
Services

Note 1: Other hardware includes clinical microscopes and accessories.

Note 2: Other software includes digital storage systems, tissue microarray software, and telepathology platforms.

Digital Pathology Market Assessment-by Application

Disease Diagnosis
Drug Discovery & Development
Education & Training
Teleconsultation

Digital Pathology Market Assessment-by End User

Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Diagnostic Laboratories

Digital Pathology Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
Middle East & Africa

Product Code: MRHC - 104749

1. Introduction

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Process
2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
2.3. Market Assessment
- 2.3.1. Market Size Estimation
  - 2.3.1.1 Bottom-up Approach
  - 2.3.1.2. Top-down Approach
  - 2.3.1.3. Growth Forecast
- 2.3.2. Market Share Analysis
2.4. Assumptions for this Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

4.1. Market Overview
4.2. Drivers
- 4.2.1. Rising Prevalence of Chronic Diseases
- 4.2.2. Increasing Adoption of Digital Pathology Solutions to Enhance Lab Efficiency
- 4.2.3. Wider Applications of Digital Pathology in Companion Diagnostics And Drug Development
4.3. Restraints
- 4.3.1. Lack of Reimbursement for Digital Pathology Services
4.4. Opportunity
- 4.4.1. Rising Demand for Personalized Medicine
- 4.4.2. Launch of Affordable Scanners for Private Pathology Practices
- 4.4.3. Developing Economies
4.5. Challenges
- 4.5.1. Legal and Regulatory Hurdles in Digital Pathology
- 4.5.2. Shortage of Trained Pathologists
4.6. Impact of COVID-19 on the Digital Pathology Market

5. Global Digital Pathology Market, by Offering

5.1. Introduction
5.2. Hardware
- 5.2.1. Slide Scanners
  - 5.2.1.1. Bright Field
  - 5.2.1.2. Other Scanners
- 5.2.2. Tissue Microarray
- 5.2.3. Other Hardware (Clinical Microscopes, Accessories)
5.3. Software
- 5.3.1. Image Analysis Software
- 5.3.2. Information Management System
- 5.3.3. Other Software (Digital Storage Systems, Tissue Microarray Software, Telepathology Platforms)
5.4. Services

6. Global Digital Pathology Market, by Application

6.1. Introduction
6.2. Diagnostics
6.3. Drug Discovery & Development
6.4. Education & Training
6.5. Teleconsultation

7. Global Digital Pathology Market, by End User

7.1. Introduction
7.2. Hospitals & Clinics
7.3. Pharmaceutical & Biotechnology Companies
7.4. Academic & Research Institutes
7.5. Diagnostic Laboratories

8. Digital Pathology Market, by Geography

8.1. Introduction
8.2. North America
- 8.2.1. U.S.
- 8.2.2. Canada
8.3. Europe
- 8.3.1. Germany
- 8.3.2. U.K.
- 8.3.3. France
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific (APAC)
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America (LATAM)
- 8.5.1. Brazil
- 8.5.2. Mexico
- 8.5.3. Rest of Latin America (RoLATAM)
8.6. Middle East & Africa

9. Competitive Landscape

9.1 Introduction
9.2 Key Growth Strategies
9.3 Competitive Benchmarking
9.4. Market Share Analysis (2022)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

10.1. 3DHISTECH Ltd.
10.2. Leica Microsystems (a subsidiary of Danaher Corporation)
10.3. Hamamatsu Photonics K.K.
10.4. Nikon Corporation
10.5. Visiopharm A/S
10.6. Koninklijke Philips N.V.
10.7. F. Hoffmann-La Roche Ltd.
10.8. Glencoe Software, Inc.
10.9. PerkinElmer Inc.
10.10. XIFIN, Inc.

11. Appendix

11.1. Questionnaire
11.2. Available Customization